Max Healthcare Institute (543220) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
17 Aug, 2026Company overview
Operates 21 healthcare facilities with over 6,100 beds, making it India's second largest hospital chain by revenue and EBITDA.
73% of beds are located in metro cities, with a strong presence in Delhi NCR and Mumbai.
Market capitalization reached ₹1.1 lakh crore ($11.6 billion) with a 35% CAGR from June 2021 to June 2026.
Vision centers on clinical excellence, patient-centric care, and sustainable growth supported by advanced technology and research.
Distinguished board and dynamic management team with expertise in healthcare, finance, and operations.
Growth strategy and expansion
Focus on optimizing existing infrastructure, expanding bed capacity through brownfield and greenfield projects, and pursuing asset-light models.
Strong track record of successful acquisitions and integrations, adding ~1,300 beds in the last 18 months.
Plans to add ~4,000 beds in the next 3-4 years, with potential to expand by ~8,300 beds overall.
Leverages digital platforms, homecare, and pathology businesses for capital-light growth.
Maintains a minimally leveraged balance sheet and strong free cash flow to support future M&A.
Operational and financial performance
Achieved 22% revenue CAGR and 33% EBITDA CAGR over the last five years.
Q1 FY27 occupancy at 75%, ARPOB at ₹82,000, and EBITDA margin at ~25%.
Q1 FY27 gross revenue grew 15% YoY to ₹2,982 crore, with profit after tax at ₹357 crore.
Annual FY26 gross revenue was ₹10,538 crore, with a profit after tax of ₹1,631 crore and EBITDA margin of 26.2%.
Strong cash generation from operations and headroom to raise debt for expansion.
Latest events from Max Healthcare Institute
- Revenue and EBITDA rose 16% and 15% YoY, driven by expansion and digital growth.543220
Q1 26/27 - FY26 revenue rose 16% YoY to INR 10,538 crore, with 22% PAT growth and major capacity expansions.543220
Q4 25/26 - Q3 FY26 delivered strong growth, with expansion, digital gains, and regulatory impacts shaping outlook.543220
Q3 25/26 - Q2 FY26 delivered 21% revenue and 23% EBITDA growth, driven by expansion and digital gains.543220
Q2 25/26 - Revenue up 27% YoY, EBITDA up 23%, and PAT up 17% amid robust expansion and digital growth.543220
Q1 25/26 - Q1 FY25 saw 18% revenue growth, high occupancy, and strong expansion momentum.543220
Q1 24/25 - Strong revenue and EBITDA growth, major acquisitions, and expansion marked the quarter.543220
Q2 24/25 - Q3 FY25 revenue rose 34% with strong EBITDA, major expansions, and Jaypee Healthcare acquisition.543220
Q3 24/25 - FY25 revenue rose 26% YoY to INR 9,065 Cr, with robust EBITDA growth and major expansions.543220
Q4 24/25